Valuation: Beam Therapeutics Inc.

Market Cap 2.72B 2.36B 2.2B 2.02B 3.79B 259B 3.85B 25.8B 10.11B 130B 10.22B 10B 430B P/E 2026 *
-6.24x
P/E 2027 * -5.88x
Enterprise Value 1.81B 1.56B 1.46B 1.34B 2.52B 172B 2.56B 17.12B 6.71B 86.16B 6.78B 6.64B 285B EV / Sales 2026 *
33.6x
EV / Sales 2027 * 20.5x
Free-Float
98.25%
Yield 2026 *
-
Yield 2027 * -
1 day+0.84%
1 week+3.74%
Current month+7.68%
1 month-22.20%
3 months-15.03%
6 months+3.62%
Current year-0.87%
1 week 24.67
Extreme 24.67
28.47
1 month 24.67
Extreme 24.67
37.78
Current year 21.63
Extreme 21.63
38.26
1 year 15.6
Extreme 15.6
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
116.91
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2017
Director of Finance/CFO 48 19/12/2024
President 57 24/01/2020
Director TitleAgeSince
Director/Board Member 48 01/01/2017
Director/Board Member 75 01/05/2018
Director/Board Member 56 10/10/2019
Date Insider Type Main position Quantity % Market Cap.
27/7/26 Sell

Chief Technology Officer

-16,667 0.0162%
30/6/26 Fiscal year

Chief Executive Officer

75,000 0.0729%
30/6/26 Sell

Chief Technology Officer

-373 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+3.74%+50.16%+1.33% 2.72B
+0.99%+0.35%+4.91%+16.06% 48.7B
+3.71%+6.75%+459.45%+557.32% 42.05B
+2.70%+0.38%+34.49%+10.04% 38.26B
+5.60%+8.13%+16.67%+72.18% 37.5B
+2.21%+4.89%+17.24%+51.64% 31.44B
+2.23%+1.73% - - 16.47B
+0.97%+2.14%+37.25%+128.28% 16.33B
-0.11%+1.75%+8.05%+18.47% 13.98B
+0.75%+14.01%+77.94%+29.28% 12.68B
Average +1.99%+3.04%+78.46%+98.29% 26.01B
Weighted average by Cap. +2.50%+2.32%+98.06%+129.94%

Financials

2026 *2027 *
Net sales 53.78M 46.54M 43.44M 39.87M 74.95M 5.12B 76.1M 510M 200M 2.57B 202M 198M 8.48B 73.09M 63.24M 59.03M 54.19M 102M 6.96B 103M 693M 271M 3.49B 274M 268M 11.53B
Net income -461M -399M -372M -342M -642M -43.87B -652M -4.37B -1.71B -21.98B -1.73B -1.69B -72.7B -519M -449M -419M -385M -723M -49.38B -734M -4.92B -1.93B -24.74B -1.95B -1.91B -81.83B
Net Debt -916M -793M -740M -679M -1.28B -87.24B -1.3B -8.68B -3.4B -43.7B -3.44B -3.37B -145B -1.22B -1.06B -987M -906M -1.7B -116B -1.73B -11.58B -4.54B -58.26B -4.59B -4.49B -193B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
540
Date Price Change Volume
07/08/26 USD 27.48 +0.84% 1,322,993
06/08/26 USD 27.25 +0.66% 1,168,605
05/08/26 USD 27.07 -4.51% 2,056,909
04/08/26 USD 28.35 +9.42% 2,151,134
03/08/26 USD 25.91 +1.53% 1,295,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
27.25USD
Average target price
52.15USD
Spread / Average Target
+91.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock